Alethia’s pipeline places great emphasis on the development of monoclonal antibodies generated against its disease-specific targets. AB-16B5 is a humanized IgG2 monoclonal antibody which targets tumor-associated secreted clusterin for the inhibition of cancer-associated epithelial-to-mesenchymal transition (EMT). AB-16B5 is currently under study in animal models of invasive cancers and shows positive pre-clinical results in representative models of prostate and beast cancer.
AB-3D3 is a humanized IgG1 monoclonal antibody developed against KAAG1, a small cell-surface protein, for the treatment of ovarian cancer. AB-3D3 is currently under evaluation in animal models. Our studies have shown that antibodies against KAAG1 reduce the number of micrometastsic tumors in animal models. We have also recently confirmed that the antigen is expressed on tumors cells isolated from the ascites fluid of an ovarian cancer patient. The ability to target an antigen such as KAAG1 in recurrent ovarian cancer has tremendous potential to address these urgent needs.
AB-25E9 is a humanized IgG2 monoclonal antibody targeting Siglec-15, a cell-surface protein essential for osteoclast differentiation. AB-25E9 is currently under evaluation in models of severe bone loss.
